DLL4 and type 1 diabetes mellitus: Anti-DLL4 treatment has a similar effect to that of islet transplant in human T1D patients monitored using non-insulin-modified frequently sampled intravenous glucose tolerance (NIM-FSIGT) using euglycemic clamps, where, the second phase of insulin secretion post-transplantation was markedly increased to 83% as compared to the first phase (15%) (Vethakkan et al., 2010).